Preloader

FOCUS 77L is an NGS-based liquid biopsy assay designed for patients with insufficient tissue for molecular testing, when repeat tissue biopsy is not feasible, and/or in cases of disease progression or suspected acquired resistance. By analyzing ctDNA in blood, it enables longitudinal monitoring of the tumor’s molecular profile.

The assay demonstrates high concordance with tissue-based genomic profiling and, in accordance with international guidelines (ASCO and ESMO), enables the sensitive detection of resistance-associated alterations that may emerge during treatment.

Cancer Type: All solid tumors*
* For patients with non-small cell lung cancer (NSCLC) or colorectal cancer (CRC) who have progressive disease and insufficient tissue for molecular analysis, liquid biopsy (cfDNA) is recognized by NCCN Guidelines as a critical diagnostic approach.

Technical Specifications

Method: NGS – Hybrid Capture

Coverage: ~10,000x (High Sensitivity)

Coverage: 77 Genes (Included in NCCN guidelines)

ALK, NTRK1, FGFR2, FGFR3, RET, and ROS1 (Fusions); EGFR, ERBB2, and MET (CNVs) genes 

Genetic Alterations Analyzed:

Detects SNV, Indel, Fusion, and CNV variants with a limit of detection (LoD) down to 0.1%.

Assay Kit:  ROCHE AVENIO ctDNA kit 

Sequencing System: İlumina NextSeq 550 DX (CE-IVD approved)

Bioinformatics System: Avenio

Accreditation: GENQA External Quality Assessment (EQA) & CAP Accreditation

Other Features:

The test features a Positive Predictive Value (PPV) of >99%, significantly minimizing false-positive rates.

Sample Requirements: 2 Streck Tubes

Turnaround Time (TAT): 10–14 days

* Please contact our laboratory for detailed sample submission requirements.
FOCUS 77 Liquid is performed in accordance with the requirements of the EMQN External Quality Assessment (EQA) program.

 

Focus 77 LiquidRoche_Logo

Focus 77 Liquid

//
Our customer support team is here to answer your questions!